biostudies-literatureUnknown13Serrano Domingo JJ<h4>Introduction</h4>Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a poorer survival in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). We aimed to analyze whether some cardiovascular or neurological disorders, together with other medical and urological complications, may have an effect on survival outcomes, at baseline and during treatment from patients treated with androgen pathway inhibitors (API).<h4>Material and methods</h4>A retrospective study of a consecutive series of patients diagnosed with mCRPC between 2010 and 2018 treated with API in the first line setting in a single center.<h4>Results</h4>Seventy-three patients met the inclusion criteria. Baseline prognostTherapeutic advances in urology17562872211043341https://www.ebi.ac.uk/biostudies/studies/S-EPMC8451255biostudies-literatureThe effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.PMC8451255Alvarez Rodriguez SBurgos Revilla JBarquin Garcia AAlonso Gordoa TMolina-Cerrillo JCarrato AMartinez Saez OLorca Alvaro JSerrano Domingo JJfalseThe effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.<h4>Introduction</h4>Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a poorer survival in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). We aimed to analyze whether some cardiovascular or neurological disorders, together with other medical and urological complications, may have an effect on survival outcomes, at baseline and during treatment from patients treated with androgen pathway inhibitors (API).<h4>Material and methods</h4>A retrospective study of a consecutive series of patients diagnosed with mCRPC between 2010 and 2018 treated with API in the first line setting in a single center.<h4>Results</h4>Seventy-three patients met the inclusion criteria. Baseline prognost2021-01-01T00:00:00Z2021 Jan-Dec2025-04-04T14:53:24.497Z2022-02-11T11:15:19.629ZS-EPMC84512553455266610.1177/17562872211043341